PD98059

目錄號：S1177 Purity: 99.92%

PD98059 是一種非ATP競爭性的MEK抑制劑，無細(xì)胞試驗(yàn)中IC50為2 μM，特異性抑制MEK-1介導(dǎo)的MAPK激活；不直接抑制ERK1或ERK2。PD98059 是一種aryl hydrocarbon receptor (AHR)的配體并起到拮抗劑的功能。

PD98059 Chemical Structure

CAS: 167869-21-8

規(guī)格	價格	庫存
10mM (1mL in DMSO)	1570	現(xiàn)貨
10mg	1213.08	現(xiàn)貨
50mg	3845.73	現(xiàn)貨
200mg	5489.52	現(xiàn)貨
1g	10401.3	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 [email protected]

產(chǎn)品質(zhì)控

批次：純度： 99.92%

99.92

PD98059相關(guān)產(chǎn)品

相關(guān)靶點(diǎn)	MEK1 MEK1/2 MEK2 MEK5	點(diǎn)擊展開
相關(guān)產(chǎn)品	PD0325901 (Mirdametinib) U0126-EtOH PD184352 (CI-1040) BIX 02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 BIX 02188 GDC-0623 SL-327 Myricetin BI-847325 PD318088 APS-2-79 HCl	點(diǎn)擊展開
相關(guān)化合物庫	激酶抑制劑庫 MAPK抑制劑庫細(xì)胞周期化合物庫 TGF-beta/Smad信號通路庫抗阿爾茨海默病化合物庫	點(diǎn)擊展開

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時間	活性描述	文獻(xiàn)信息(PMID)
NUGC2	Function Assay	50 μM	48 h	increases expression of HLA-A02 or HLA-A24 molecules	24244023
SGC-7901?	Apoptosis Assay	20 μM	24 h	inhibits CP-mediated apoptosis	24241351
MG-63	Function Assay	20 μM	0.5 h	blocks the CH-induced phosphorylated ELK1 protein expression	24239640
HCT-15	Apoptosis Assay		1 h	abolishes the protective effects of PGE2?against curcumin-induced apoptosis	25431425
786-O	Apoptosis Assay	50?μM	24 h	potentiates?the pro-apoptotic effects of NC	24508476
HepG2?	Growth Inhibition Assay	20 μM	24 h	suppresses TGF-β1-induced cell proliferation and invasion	25560488
SW480	Function Assay	20?μM	1?h	reduces the expression of ATF3 protein	25447816
MDA-MB-231	Function Assay	25 μM	2-3 h	decreases p-ERK1/2 and S100A4 expression	25555875
HepG2?	Function Assay	10 μM	5 h	blocks phosphorylated MAPKs induced by exogenous TGF-β1	25560488
MCF-7?	Function Assay	10 μM	1 h	inhibits IL-18-enhanced cell migration	25727011
H1355	Function Assay	25 μM	1 h	blunts the B[a]P-induced increase in phospho-Chk1 and phospho-ERK expression	25769181
PC12	Function assay			Inhibition of nerve growth factor-mediated MAP kinase activity in human PC12 cells, IC50 = 2 μM.	18077363
HT-29	Antiproliferative assay		5 days	Antiproliferative activity against human HT-29 cells after 5 days by WST1 assay, IC50 = 4 μM.	25078316
IEC6	Function assay		5 mins	Inhibition of MEK1/2 in rat IEC6 cells assessed as reduction in ERK1/2 loop phosphorylation dosed 30 mins before to stimulation with 10% serum for 5 mins by immunoblotting method, IC50 = 4.2 μM.	25078316
NG 108-15	Function assay			Concentration required to abolish MAPK activity in mouse neuroblastoma and rat glioma hybrid NG 108-15 cells, Activity = 10 μM.	15537354
PC12	Function assay	10 uM	5 hrs	Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with JNK inhibitor SP600125 for 1 hr before compound addition by Western blot analysis	21345685
SW480	Function Assay	10 μM	20 h	suppresses the CRT activity	24324366
HEK 293	Function Assay	10 μM	5 h	inhibits Wnt-induced β-catenin/TCF4 activity and nuclear β-catenin accumulation	24324366
HEK 293	Function Assay	10 μM	5 h	suppresses the CRT activity	24324366
HL-60?	Function Assay	10/20 μM	1 h	inhibits the?N. chinensisextract?induced differentiation into granulocytes	24357020
HL-60	Function Assay	2 μM	16 h	inhibits the association of pS621 Raf-1 and NFATc3, and the RA-induced phosphorylation of nuclear NFATc3	24330068
HeLa	Function Assay	50 μM	0.5 h	blocks TRX-1 nuclear migration and TXNIP down-regulation	24376827
HUVECs	Function Assay	10?μM	1 h	inhibits the HDL reduced COX-2 expression and PGI-2 release	24385109
MCF-7	Function Assay	10?μM	10/30 min	reduces the UTP-dependent ERK phosphorylation	24390819
HGC-27	Apoptosis Assay	1 μM	1 h	suppresses RAD001 plus MK-2206-induced cell viability loss	24416349
PC3?	Apoptosis Assay	50 μM	0.5 h	inhibits MHY-449-induced apoptosis?	24424889
HPAEpiCs?	Function Assay	30 μM	1 h	inhibits TNF-α stimulated p42/p44 MAPK phosphorylation	24441870
BeWo	Function Assay	10?μM	2 h	inhibits ERK1/2	24433846
A498	Apoptosis Assay	50?μM	24 h	potentiates?the pro-apoptotic effects of NC	24508476
NHBE	Function Assay	2/20 μM	2 h	attenuates IL-33 stimulated CXCL8/IL-8 secretion	24479526
A375	Cell Invasion Assay	10–20 μM	24 h	reduces melanoma cell invasion	24466036
HBMEC	Function Assay	10 μM	1 h	blocks VEGF-induced EphA2 expression	24458982
A549	Function Assay	30 μM	0.5 h	inhibits thrombin-induced C/EBPβ Thr235?phosphorylation	24277696
HCSMCs	Growth Inhibition Assay	10 μM	24 h	blocks FABP4-induced HCASMC proliferation	24312381
PANC-1	Function Assay	20 μM	48 h	inhibits the expression of Δ6D in response to the PPARδ?agonist?	24294133
Raji?	Function Assay	10 μM	1 h	blocks hsBAFF induced Erk1/2 phosphorylation	24269630
Raji?	Growth Inhibition Assay	10 μM	1 h	inhibits the basal or hsBAFF-stimulated cell proliferation and viability	24269630
TE5	Function Assay	50 μM	48 h	upregulates the expression of HLA class I	24244023
TE1	Function Assay	50 μM	48 h	upregulates the expression of HLA class I	24244023
TE3	Function Assay	50 μM	48 h	upregulates the expression of HLA class I	24244023
KYSE30	Function Assay	20/50/100 μM	48 h	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE1	Function Assay	20/50/100 μM	48 h	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE4	Function Assay	20/50/100 μM	48 h	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
HT29	Function Assay	10 μM	2 h	inhibits of JAK2, ERK1/2 and STAT3 phosphorylation	24265293
HepG2	Apoptosis Assay	20 μM	24 h	inhibits ERK1/2 phosphorylation and enhances VB1-induced apoptosis	24247909
HepG2	Function Assay	20 μM	2 h	enhances VB1-induced FOXO3a transcriptional activity	24247909
MDA-MB-231	Function assay	50 uM		Downregulation of MMP9 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
MKN45	Apoptosis Assay	10 μM?	24 h	increases the DAPT-induced cell apoptosis	23792588
BxPC-3 cells	Growth Inhibition Assay	20?μM	0.5 h	inhibits VEGF-A-regulated HUVEC growth and tube formation induced by PAR-2 AP	23764046
NB4?	Apoptosis Assay	10/20/60 μM	1.5 h	decreases cell viability co-treated	23735541
HepG2?	Function Assay	20?μM	24 h	inhibits the HO-1 protein expression co-treated	23707609
HUVECs	Apoptosis Assay	2/4 μM	24/48 h	induces cell death	23707520
KG-1?	Apoptosis Assay	20?μM	12 h	enhances cell apoptosis induced by S1	23706691
AML 1#	Apoptosis Assay	20?μM	12 h	enhances cell apoptosis induced by S1	23706691
A2780?	Function Assay	20?μM	1 h	blocks DTCD-induced DR5 expression	23696862
KYSE30	Function Assay	50 μM	48 h	upregulates the expression of HLA class I	24244023
MKN45	Growth Inhibition Assay	10 μM?	24/48/72 h	inhibits cell growth co-treated with DAPT	23792588
SGC7901	Growth Inhibition Assay	10 μM?	24/48/72 h	inhibits cell growth co-treated with DAPT	23792588
MKN45	Function Assay	10 μM?	24 h	inhibits the expression of phosphorylated ERK1/2	23792588
SGC7901	Apoptosis Assay	10 μM?	24 h	increases the DAPT-induced cell apoptosis	23792588
HUASMCs	Function Assay	10 μM?	24 h	diminishes Ang II-caused SOCS3 mRNA and protein expression?	23816468
SGC7901	Function Assay	10 μM?	24 h	inhibits the expression of phosphorylated ERK1/2	23792588
HUASMCs	Function Assay	10 μM?	24 h	inhibits Ang II-induced ERK1/2 phosphorylation level	23816468
LNCaP?	Function Assay	10 μM?	1 h	decreases the EGF upregulated p-YB-1	23838318
HUVECs	Function Assay	25 μM	1 h	increase NF-κB p65 nuclear translocation	23901008
HL60?	Function Assay	20?μM	72 h	inhibits -induced CD11b expression	23825585
NB4?	Function Assay	10 μM?	72 h	inhibits -induced CD11b expression	23825585
EPOR/CR3	Function Assay	50?μM	3 h	reduces EPO and/or IL-3-induced the tyrosine phosphorylation?	23820731
COLO205	Apoptosis Assay	10/20/40 μM	24 h	induces DNA ladder formation	24019108
BxPC-3	Function Assay	10 μM?	6 h	increase miR-143 expression	23973710
HPAF-II	Function Assay	10 μM?	6 h	increase miR-143 expression	23973710
HepG2	Function Assay	40 μM	6/12 h	inhibits the increase of p-ERK1 and p-c-Jun protein expression by PL	23942851
HL-60	Apoptosis Assay	50?μM	1 h	rescues BA145 mediated apoptosis	23948751
SGC7901	Apoptosis Assay	20?μM	1 h	inhibits apoptosis induced by IFN-α?and 5′-DFUR	24027750
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
MDA-MB-231	Function assay	50 uM		Downregulation of MMP2 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
PC12	Function assay	10 uM	5 hrs	Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK1 inhibitor PD98059 for 1 hr before compound addition by Western blot analysis	21345685
HeLa	Function assay	20 uM	3 hrs	Inhibition of ERK1/2 phosphorylation in human HeLa cells at 20 uM after 3 hrs by Western blotting analysis	23570615
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
PC12	Function assay	10 uM	5 hrs	Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK2 inhibitor U0126 for 1 hr before compound addition by Western blot analysis	21345685
MCF-7	Function Assay	20 μM	1 h	abolishes expression of phosphorylated ERK co-treatment with conjugate	24216289
7402	Apoptosis Assay	30 μM	5 d	decreases cell proliferation	24211253
HT-29	Function Assay	20?μM	48 h	reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
DLD-1?	Function Assay	20?μM	48 h	reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
7721	Apoptosis Assay	30 μM	5 d	decreases cell proliferation	24211253
SGC7901?	Apoptosis Assay	50?μM	24/48/72 h	induces apoptosis combined with JAK2 shRNA	24178240
SMMC7721	Function Assay	25/50 μM	24 h	suppresses the expression of p-Akt or p-ERK1/2?	24168056
MCF-7	Growth Inhibition Assay	10 μM	48h	reverses BNF-induced cell cycle arrest	24163404
Caco-2	Function Assay	50?μM	48h	enhances the mRNA levels of?SCNN1A,FXYD3,?LCT,?LOX,?HIF3A,?ZG16,?PDE6A?and?LGALS16?genes?co-treated with Dex	24161695
HAECs	Function Assay	10 μM	1 h	?attenuates TNF-α-stimulated ICAM-1 and VCAM-1 expression	24134657
Ca9-22	Function Assay	3 μM	1 h	abolishes the ability of HbR to induce IL-8 production	24126532
Ca9-22	Function Assay	3 μM	1/2 h	reduces HbR-induced ATF-2 phosphorylation	24126532
AGS	Function Assay	10 μM?	0.5 h	inhibits the upregulation of the IL-8 gene	24106166
Caco-2?	Apoptosis Assay	10?μM	24?h	decreases cell apoptosis induced by 5-FU	24095863
A549	Function Assay	50?μM	2 h	blocks ERK phosphorylation mediated by 1,2-NQ	24067727
HPMC	Function Assay	10?μM	48 h	reverses the changes in cell morphology induced by HGPDS	24042838
HCT-8	Apoptosis Assay	10?μM	24?h	decreases cell apoptosis induced by 5-FU	24095863
HPMC	Apoptosis Assay	10?μM	24?h	reverses decrease in cell viability induced by HGPDS	24042838
CRL-2302	Function Assay	20 μM	0.5 h	inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
MCF-7	Apoptosis Assay	20 μM	1 h	increases caspase-9 enzyme activity	24216289
HCT-15	Function Assay		1 h	attenuates PGE2-induced phosphorylation of Erk?	25431425
A549	Function Assay	30 μM	0.5 h	inhibits the thrombin-induced IL-8/CXCL8-Luc activity	24277696
MC-3	Apoptosis Assay	10 μM	24 h	potentiated MESC-induced apoptosis in cells	24270523
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	29435139
G292?	Apoptosis Assay	30?μM	2 h	restores capsaicin-induced cell death	24012930
MGC803?	Apoptosis Assay	20?μM	1 h	inhibits apoptosis induced by IFN-α?and 5′-DFUR	24027750
ARPE-19	Function Assay	20 μM	0.5 h	inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
NUGC3	Function Assay	50 μM	48 h	increases expression of HLA-A02 or HLA-A24 molecules	24244023
OE19	Function Assay	50 μM	48 h	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NCI-N87?	Function Assay	50 μM	48 h	increases expression of HLA-A02 or HLA-A24 molecules	24244023
KATOIII?	Function Assay	50 μM	48 h	increases expression of HLA-A02 or HLA-A24 molecules	24244023
MKN7	Function Assay	50 μM	48 h	increases expression of HLA-A02 or HLA-A24 molecules	24244023
TE4	Function Assay	50 μM	48 h	upregulates the expression of HLA class I	24244023
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

特性

PD98059不會抑制已經(jīng)被c-Raf磷酸化的 MEK1

靶點(diǎn)

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

體外研究(In Vitro)
體外研究活性	PD98059 要么抑制本底的MEK1，要么抑制一種被部分激活的MEK突變體，該突變體是 218 和 222號位上絲氨酸突變?yōu)楣劝彼岷笮纬傻?MEK-2E)， IC50 為2 μM. PD98059 不會抑制JNK和P38這兩個 MAPK 的同系物. PD98059會高度選擇性的抑制MEK, 因?yàn)閷ζ渌≧af 激酶, cAMP-依賴性激酶, 蛋白激酶C, v-Src, 表皮生長因子 (EGF) 受體激酶, 胰島素受體激酶, PDGF 受體激酶, 和磷脂酰肌醇(-3)激酶等在內(nèi)的一系列激酶都沒有抑制性。 PD98059 會抑制經(jīng)過PDGF刺激而活化的MAPK 和胸苷進(jìn)入 3T3 細(xì)胞， IC50分別為 ~10 μM 和 ~7 μM ^[1]。PD98059可以有效地阻止 MEK1 被Raf 或者M(jìn)EK 激酶活化， IC50為4 μM, 可以微弱地抑制MEK2被 Raf 活化， IC50 為50 μM。在KB 和 PC12 細(xì)胞中, PD98059 不會抑制MKK4 和RK激酶這兩個參與壓力和白細(xì)胞介素-1介導(dǎo)的激酶級聯(lián)反應(yīng)的MEK的同系物的活化，在Swiss 3T3 細(xì)胞中也不會通過胰島素或者表皮生長因子抑制p70 S6 激酶的活化^[2]。PD98059會在不改變細(xì)胞生存能力的情況下完全阻斷神經(jīng)生長因子(NGF)誘導(dǎo)的 PC12 細(xì)胞的分化^[3] 。PD98059會以劑量依賴性的方式抑制培養(yǎng)在含有破骨細(xì)胞分化因子培養(yǎng)基中的 RAW264.7細(xì)胞的增值，進(jìn)而導(dǎo)致TRAP陽性細(xì)胞數(shù)量明顯下降^[6]。
激酶實(shí)驗(yàn)	體外MEK激酶活性測定
激酶實(shí)驗(yàn)	在含有44-kDa GST-MAPK 或者45-kDa GST-MEK1的體系中檢測³²P被摻入蛋白 MBP中的情況。反應(yīng)體系50 μL ，含有50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP，加入10 μg GST-MEK1, 0.5 μg GST-MAPK和 40 μg MBP。30°C 孵育15 分鐘, 加入Laemmli SDS 樣品緩沖液終止反應(yīng)。磷酸化的MBP 進(jìn)行10% SDS-PAGE分析
細(xì)胞實(shí)驗(yàn)	細(xì)胞系	K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, 和K562
	濃度	溶于DMSO, 終濃度~100 μM
	孵育時間	3 天, 或者7-10天
	方法	細(xì)胞按10,000-20,000個/mL的密度接種在多孔平板中進(jìn)行單層生長。48小時后把不同濃度的PD98059 加到細(xì)胞培養(yǎng)基孵育3天。然后通過胰酶將細(xì)胞從平板中消化下來并用Coulter 計(jì)數(shù)器計(jì)數(shù)。將細(xì)胞按5,000-10,000每皿的濃度接種在35 mm的培養(yǎng)皿中，培養(yǎng)基中含有0.3% 的瓊脂和期望濃度的PD98059，讓細(xì)胞在軟瓊脂上生長.經(jīng)過7-10天的生長, 可以借助解剖顯微鏡將可見的菌落數(shù)出來。
實(shí)驗(yàn)圖片	檢測方法	檢測指標(biāo)	實(shí)驗(yàn)圖片	PMID
實(shí)驗(yàn)圖片	Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT p-JNK / JNK / Cyclin D1 p-HER2 / HER2 MMP9 / XIAP / VEGF		17482134

體內(nèi)研究(In Vivo)
體內(nèi)研究活性	在大腦缺血前30分鐘用PD98059處理小鼠可以明顯減輕傷害, 使腦梗塞的體積減小^[4]。基于胰腺的濕重和組織學(xué)研究發(fā)現(xiàn)，提前30分鐘用PD98059預(yù)處理 (10 mg/kg 靜脈注射) 然后每小時注射一次蛙皮素連續(xù)三次的小鼠可以明顯改善蛙皮素誘導(dǎo)的急性胰腺炎^[7]。卡拉膠損傷一小時后用PD98059 (10 mg/kg) 對小鼠進(jìn)行治療可以發(fā)現(xiàn)與炎癥相關(guān)的所有指標(biāo)均有所下降^[11]。
動物實(shí)驗(yàn)	Animal Models	患有急性胰腺炎的雄性Sprague–Dawley 大鼠
	Dosages	10 mg/kg
	Administration	靜脈注射

參考文獻(xiàn)
[1]https://pubmed.ncbi.nlm.nih.gov/7644477/ [2]https://pubmed.ncbi.nlm.nih.gov/7499206/ [3]https://pubmed.ncbi.nlm.nih.gov/7775407/ [4]https://pubmed.ncbi.nlm.nih.gov/12237315/ [5]https://pubmed.ncbi.nlm.nih.gov/10536014/ [6]https://pubmed.ncbi.nlm.nih.gov/12370536/ [7]https://pubmed.ncbi.nlm.nih.gov/20074457/ [8]https://pubmed.ncbi.nlm.nih.gov/11254111/ [9]https://pubmed.ncbi.nlm.nih.gov/17161815/ [10]https://pubmed.ncbi.nlm.nih.gov/14506750/ [11]https://pubmed.ncbi.nlm.nih.gov/17409429/ [12]https://pubmed.ncbi.nlm.nih.gov/9495809/ + 展開

參考文獻(xiàn)

[1]https://pubmed.ncbi.nlm.nih.gov/7644477/
[2]https://pubmed.ncbi.nlm.nih.gov/7499206/
[3]https://pubmed.ncbi.nlm.nih.gov/7775407/

[4]https://pubmed.ncbi.nlm.nih.gov/12237315/
[5]https://pubmed.ncbi.nlm.nih.gov/10536014/
[6]https://pubmed.ncbi.nlm.nih.gov/12370536/
[7]https://pubmed.ncbi.nlm.nih.gov/20074457/
[8]https://pubmed.ncbi.nlm.nih.gov/11254111/
[9]https://pubmed.ncbi.nlm.nih.gov/17161815/
[10]https://pubmed.ncbi.nlm.nih.gov/14506750/
[11]https://pubmed.ncbi.nlm.nih.gov/17409429/
[12]https://pubmed.ncbi.nlm.nih.gov/9495809/

+ 展開

化學(xué)信息&溶解度

分子量	267.28	分子式	C₁₆H₁₃NO₃
CAS號	167869-21-8	SDF	Download PD98059 SDF
Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復(fù)凍融！	1個月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 46 mg/mL ( (172.1 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 28 mg/mL ( (104.75 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解配方批次：現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑				動物體內(nèi)配方計(jì)算器
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	4%DMSO 1 30%PEG300 2 5%Tween80 3 61%ddH2O 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	1.000mg/ml (3.74mM)	以 1 mL 工作液為例，取40μL25mg/ml的澄清DMSO儲備液加到300μL PEG300中，混合均勻使其澄清；向上述體系中加入50μLTween80，混合均勻使其澄清；然后繼續(xù)加入610μL ddH2O定容至 1 mL。工作液請現(xiàn)配現(xiàn)用！
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	1.000mg/ml (3.74mM)	以 1 mL 工作液為例,取50μL20mg/ml的澄清DMSO儲備液加到400μLPEG300中,混合均勻使其澄清;向上述體系中加入50μLTween80,混合均勻使其澄清;然后繼續(xù)加入500μLddH2O定容至1mL。工作液請現(xiàn)配現(xiàn)用!

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計(jì)算器分子量計(jì)算器

動物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動物的藥量）

給藥劑量 mg/kg 動物平均體重 g 每只動物給藥體積 μL 動物數(shù)量只

第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運(yùn)輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項(xiàng)

常見問題及建議解決方法

問題 1:
How to formulate this inhibitor for i.p. injection?

回答：
You can prepare the stock of this compound by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):